BioSci BDAboutContactCategories Main MenuBiofinancingEvolving Deal TermsSell-Side AnalysisAlliance TrendsCompulsory License Provisions in Biopharma AlliancesEvolving Deal Terms Nov 1, 2020 Mark EdwardsThe Indomitable Biotech IPO Window What’s keeping it Open?Biofinancing Sep 1, 2020 Mark EdwardsRecent Trends in Oncology AlliancesAlliance Trends Jun 29, 2020 Mark Edwards“Who’s on First?” Biopharma Licenses from the Seller’s PerspectiveEvolving Deal Terms Apr 24, 2020 Mark EdwardsAntiviral Alliances in the Shadow of COVID-19Alliance Trends Apr 5, 2020 Mark EdwardsContingent Value Rights Waiting for the DoughEvolving Deal Terms Mar 8, 2020 Mark EdwardsNegotiating “What If” Opt-in and Opt-out Provisions in Biopharma AlliancesAlliance Trends Nov 9, 2019 Mark EdwardsYou Had Me at “Hello” The Remarkable Growth of Upfront Payments in Biopharma AlliancesEvolving Deal Terms May 30, 2019 Mark EdwardsRecent Trends in Effective Royalty Rates of Biopharma AlliancesAlliance Trends Feb 5, 2019 Mark EdwardsBiopharma Milestone Payments Negotiating an Equitable Value AllocationEvolving Deal Terms Jan 6, 2019 Mark EdwardsImmuno-Oncology Alliances Command Big Deal PremiumsAlliance Trends Oct 13, 2018 Mark EdwardsRecent Trends & How Far You Can GoEvolving Deal Terms Jun 8, 2018 Mark EdwardsSharing the Wealth Recent Trends in Biopharma SublicensingEvolving Deal Terms Feb 18, 2018 Mark EdwardsThe Best Biotech IPO Window ...That Money Can Buy!Biofinancing Jan 1, 2018 Mark EdwardsChanging the Deal How Far Can You Go & How OftenAlliance Trends Oct 12, 2017 Mark EdwardsDawn of a Post-Venture Era: The New Face of Innovation & Translational ResearchBiofinancing Jun 25, 2017 Mark EdwardsEffective Royalty Rates in Biopharma Alliances What They Are and Why Use Them in NegotiationsEvolving Deal Terms Mar 25, 2017 Mark EdwardsYours, Mine & Ours Partnering Compounds GloballyAlliance Trends Oct 30, 2016 Mark EdwardsTop Pharma Vs. Major Biotech Who is Biopharma’s Favorite Alliance Partner?Evolving Deal Terms Jun 4, 2016 Mark EdwardsOrphan Drug AlliancesAlliance Trends Mar 23, 2016 Mark EdwardsCo-Promotion in Biopharma Agreements Success is in the DetailsEvolving Deal Terms Feb 25, 2016 Mark EdwardsTrends in University Licenses How Healthy is the Seed Corn?Alliance Trends Feb 15, 2016 Mark EdwardsThe BioPharma Industry in 2015 As Good as it GetsBiofinancing Oct 25, 2015 Mark EdwardsDuration of Royalty Obligations ’Til Death Do Us Part?Alliance Trends Oct 23, 2015 Mark EdwardsRe‐emergence of Platform Technologies Gonna Party Like It’s 1999Evolving Deal Terms May 13, 2015 Mark Edwards2014 Year in Review IPOs, Financings & AlliancesBiofinancing Jan 5, 2015 Mark EdwardsSales Milestones Bridging the Valuation GapAlliance Trends Nov 21, 2014 Mark EdwardsDemand Dividend A New Investment Vehicle for Financing Biotech CompaniesBiofinancing Feb 11, 2013 Mark EdwardsBiotech IPOs Springboard for SuccessBiofinancing Jan 24, 2013 Mark EdwardsBiotech Sell Side Research A Retrospective AnalysisSell-Side Analysis Jan 24, 2013 Mark Edwards